Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies

Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies

196
UNKNOWN
G.I. and Other Associated Cancers Research Group

Determining and quantifying the types of mucin core proteins to which CA19-9 is attached will result in assays with improved performance characteristics compared to CA19-9 alone.

Specific Aim 1) Utilize newly developed and to be developed antibodies against the mucin core proteins MUC1, MUC4, and MUC17 to develop an improved serum assay for pancreatic adenocarcinoma. Specific Aim 2) Develop and utilize a set of monoclonal antibodies that recognize serum forms of distinct mucin core proteins, utilize these to improve the diagnostic capability of the CA 19-9 type tests for nonmalignant, premalignant and malignant lesions of the pancreas, and evaluate the capability of the test to discriminate pancreatic cancer from other adenocarcinomas.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 6/2/2018
Thank you to everyone to made the 10th EDRN Scientific Workshop a success. The next event is the 33rd EDRN Steering Committee Meeting from September 5-6, 2018 in Boston, MA. Details will be available soon.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.